Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.52 |
| ▸ | ATP4A | P20648 | 9/20 | 0.43 |
| ▸ | ATP4B | P51164 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518701 | 0.88 | MAPK10 (1.00) | MAPK10MAPK9MAPK8 | |
| SCHEMBL3746644 | 0.87 | MAPK10 (0.72) | MAPK10MAPK9MAPK8ATP4AATP4B | |
| SCHEMBL1518836 | 0.81 | MAPK10 (1.00) | MAPK10MAPK9MAPK8 | |
| SCHEMBL3747826 | 0.81 | MAPK10 (0.72) | MAPK10MAPK9MAPK8 | |
| SCHEMBL3752602 | 0.80 | MAPK10 (0.70) | MAPK10MAPK9MAPK8ATP4AATP4B | |
| SCHEMBL8360670 | 0.79 | MAPK10 (0.79) | MAPK10MAPK9MAPK8 | |
| SCHEMBL4020855 | 0.79 | MAPK10 (0.76) | MAPK10MAPK9MAPK8 | |
| SCHEMBL3751308 | 0.79 | MAPK10 (0.72) | MAPK10MAPK9MAPK8ATP4AATP4B | |
| SCHEMBL4026695 | 0.79 | MAPK10 (0.81) | MAPK10MAPK9MAPK8 | |
| SCHEMBL1518907 | 0.78 | MAPK10 (1.00) | MAPK10MAPK9MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | claimed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | claimed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | claimed |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-04-19 | — | — | US | claimed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | disclosed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | disclosed |
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MERCK SERONO SA (CH) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162794-A1 | Benzazole derivatives and their use as jnk modulators | MAPK1, MAPK3, MAPKAPK2 | MAPK10 46/4885MAPK9 24/4885MAPK8 10/4885 |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | MAPK10 3/4885MAPK9 28/4885MAPK8 12/4885 |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | GPR119, GLS2, GLS | MAPK10 3255/4885MAPK9 4264/4885MAPK8 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.